CCI-779 in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
This study has been completed.
NCIC Clinical Trials Group
Information provided by (Responsible Party):
National Cancer Institute (NCI)
First received: November 4, 2003
Last updated: January 24, 2014
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||August 2009|
|Primary Completion Date:||May 2009 (Final data collection date for primary outcome measure)|
Oza AM, Elit L, Provencher D, et al.: A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. [Abstract] J Clin Oncol 26 (Suppl 15): A-5516, 2008.